225 related articles for article (PubMed ID: 24006371)
1. An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.
Berger V; Richter F; Zettlitz K; Unverdorben F; Scheurich P; Herrmann A; Pfizenmaier K; Kontermann RE
Protein Eng Des Sel; 2013 Oct; 26(10):581-7. PubMed ID: 24006371
[TBL] [Abstract][Full Text] [Related]
2. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.
Kontermann RE; Münkel S; Neumeyer J; Müller D; Branschädel M; Scheurich P; Pfizenmaier K
J Immunother; 2008 Apr; 31(3):225-34. PubMed ID: 18317365
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension.
Goodall LJ; Ovecka M; Rycroft D; Friel SL; Sanderson A; Mistry P; Davies ML; Stoop AA
PLoS One; 2015; 10(9):e0137065. PubMed ID: 26352810
[TBL] [Abstract][Full Text] [Related]
4. Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc.
Richter F; Seifert O; Herrmann A; Pfizenmaier K; Kontermann RE
MAbs; 2019; 11(4):653-665. PubMed ID: 30929560
[TBL] [Abstract][Full Text] [Related]
5. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody.
Zettlitz KA; Lorenz V; Landauer K; Münkel S; Herrmann A; Scheurich P; Pfizenmaier K; Kontermann R
MAbs; 2010; 2(6):639-47. PubMed ID: 20935477
[TBL] [Abstract][Full Text] [Related]
6. Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity.
Richter F; Zettlitz KA; Seifert O; Herrmann A; Scheurich P; Pfizenmaier K; Kontermann RE
MAbs; 2019 Jan; 11(1):166-177. PubMed ID: 30252601
[TBL] [Abstract][Full Text] [Related]
7. Construction of an anti-IL-1β scfv and TNFRI fusion protein and its therapeutic effect on RA mice model.
Kan F; Ren G; Guo M; Qi J; Zhang Y; Han Y; Zhang Y; Li D
Curr Pharm Biotechnol; 2014; 14(12):1048-61. PubMed ID: 24433504
[TBL] [Abstract][Full Text] [Related]
8. Fusion of HSA influences TNF-α neutralizing activity of shTNFRs.
Zhan J; Chen Y; Yuan HY; Li H; Lu H
Biotechnol Lett; 2012 Mar; 34(3):417-23. PubMed ID: 22083716
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
10. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.
Vendel MC; Favis M; Snyder WB; Huang F; Capili AD; Dong J; Glaser SM; Miller BR; Demarest SJ
Arch Biochem Biophys; 2012 Oct; 526(2):188-93. PubMed ID: 22230329
[TBL] [Abstract][Full Text] [Related]
11. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.
Wüest T; Gerlach E; Banerjee D; Gerspach J; Moosmayer D; Pfizenmaier K
Oncogene; 2002 Jun; 21(27):4257-65. PubMed ID: 12082613
[TBL] [Abstract][Full Text] [Related]
12. Superior serum half life of albumin tagged TNF ligands.
Müller N; Schneider B; Pfizenmaier K; Wajant H
Biochem Biophys Res Commun; 2010 Jun; 396(4):793-9. PubMed ID: 20447380
[TBL] [Abstract][Full Text] [Related]
13. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
Mukai Y; Shibata H; Nakamura T; Yoshioka Y; Abe Y; Nomura T; Taniai M; Ohta T; Ikemizu S; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
J Mol Biol; 2009 Jan; 385(4):1221-9. PubMed ID: 19084540
[TBL] [Abstract][Full Text] [Related]
14. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody.
Igawa T; Tsunoda H; Kikuchi Y; Yoshida M; Tanaka M; Koga A; Sekimori Y; Orita T; Aso Y; Hattori K; Tsuchiya M
Protein Eng Des Sel; 2010 Aug; 23(8):667-77. PubMed ID: 20576629
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity.
Richter F; Liebig T; Guenzi E; Herrmann A; Scheurich P; Pfizenmaier K; Kontermann RE
PLoS One; 2013; 8(8):e72156. PubMed ID: 23977237
[TBL] [Abstract][Full Text] [Related]
16. Construction, purification, and characterization of anti-BAFF scFv-Fc fusion antibody expressed in CHO/dhfr- cells.
Cao M; Cao P; Yan H; Lu W; Ren F; Hu Y; Zhang S
Appl Biochem Biotechnol; 2009 Jun; 157(3):562-74. PubMed ID: 19099209
[TBL] [Abstract][Full Text] [Related]
17. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A.
Unverdorben F; Färber-Schwarz A; Richter F; Hutt M; Kontermann RE
Protein Eng Des Sel; 2012 Feb; 25(2):81-8. PubMed ID: 22238430
[TBL] [Abstract][Full Text] [Related]
18. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
19. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.
Seifert O; Plappert A; Heidel N; Fellermeier S; Messerschmidt SK; Richter F; Kontermann RE
Protein Eng Des Sel; 2012 Oct; 25(10):603-12. PubMed ID: 22988132
[TBL] [Abstract][Full Text] [Related]
20. A trimeric anti-HER2/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia.
Huang TH; Morrison SL
J Pharmacol Exp Ther; 2006 Mar; 316(3):983-91. PubMed ID: 16291729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
